Abstract |
Surrogate end points of renal failure are instrumental to the testing of new treatments in patients with chronic kidney disease, the natural history of which is characterized by a slow, asymptomatic decline in renal function. The magnitude of proteinuria is widely recognized as a marker of the severity of glomerulopathy. Population-based studies have identified proteinuria as a predictor of future decline in glomerular filtration rate and of the development of end-stage renal disease. More importantly, a reduction in proteinuria invariably translates into a protection from renal function decline in patients with diabetic and nondiabetic renal disease with overt proteinuria. Thus, proteinuria should be considered a valuable surrogate end point for clinical trials in patients with proteinuric renal diseases.
|
Authors | Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi |
Journal | Nature reviews. Nephrology
(Nat Rev Nephrol)
Vol. 8
Issue 5
Pg. 301-6
(Mar 06 2012)
ISSN: 1759-507X [Electronic] England |
PMID | 22391456
(Publication Type: Journal Article, Review)
|
Chemical References |
- Acute-Phase Proteins
- Biomarkers
- Fatty Acid-Binding Proteins
- LCN2 protein, human
- Lipocalin-2
- Lipocalins
- Proto-Oncogene Proteins
|
Topics |
- Acute-Phase Proteins
(urine)
- Biomarkers
(analysis)
- Diabetic Nephropathies
(diagnosis, epidemiology)
- Disease Progression
- Fatty Acid-Binding Proteins
(urine)
- Glomerular Filtration Rate
- Humans
- Kidney Failure, Chronic
(complications, therapy, urine)
- Lipocalin-2
- Lipocalins
(urine)
- Proteinuria
(complications)
- Proto-Oncogene Proteins
(urine)
|